Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintenance of electrolyte balance; dextrose provides caloric support; sodium chloride provides sodium and chloride ions for fluid and electrolyte replacement.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous fluid and electrolyte replenishment,Treatment of hypokalemia,Maintenance of hydration and electrolyte balance
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; adult dose is 1000 m L to 2000 m L per day, providing 20-40 m Eq potassium, 50-100 g dextrose, and 77-154 m Eq sodium, administered at a rate of 125-200 m L/hour based on clinical status and serum potassium.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Potassium: terminal half-life is approximately 4-6 hours under normal renal function; prolonged in renal impairment. Dextrose: not applicable as it is rapidly metabolized. Sodium: half-life approximately 4-6 hours, dependent on renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is not metabolized; dextrose is metabolized via glycolysis and citric acid cycle; sodium and chloride are not metabolized.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Potassium: primarily renal (>90% excreted by kidneys), with small amounts lost in feces and sweat. Dextrose: metabolized to CO2 and water, minimal renal excretion. Sodium: primarily renal excretion (90-95%), with minor losses in feces and sweat. Chloride: primarily renal excretion (95%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Potassium: negligible (<1% bound). Dextrose: not bound. Sodium: negligible. Chloride: negligible.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Potassium: Vd approximately 0.5-0.6 L/kg, reflecting distribution primarily in extracellular fluid and cellular uptake. Dextrose: Vd equivalent to total body water (~0.6 L/kg). Sodium: Vd approximately 0.5-0.6 L/kg (extracellular fluid).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% bioavailability.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR 30-50 m L/min: administer with caution and monitor serum potassium, reduce infusion rate by 25-50%. For GFR 15-29 m L/min: reduce dose by 50-75% and monitor closely. For GFR <15 m L/min: avoid use or use only if absolutely necessary with extreme caution and frequent monitoring.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
For Child-Pugh A: no adjustment necessary. For Child-Pugh B: reduce infusion rate by 50% and monitor serum potassium. For Child-Pugh C: avoid use due to risk of hyperkalemia and volume overload.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion; dose based on weight: 2-4 m Eq/kg/day of potassium, 5-10 mg/kg/min of dextrose, and 2-4 m Eq/kg/day of sodium. Typical infusion rate: 0.5-1 m Eq/kg/hour of potassium. Adjust based on serum electrolytes and glucose.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at the lower end of the adult dosing range (1000 m L per day) and titrate slowly. Monitor serum potassium, renal function, and fluid status closely due to increased risk of hyperkalemia and volume overload.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Must be diluted before use; concentrated potassium solutions can cause fatal cardiac arrest if administered rapidly or in undiluted form.
None.
Use caution in patients with severe renal impairment, heart disease, or conditions predisposing to hyperkalemia. Monitor serum potassium and ECG during infusion. Avoid rapid infusion to prevent hyperkalemia.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia, severe renal failure (with oliguria or anuria), untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, or concurrent use with potassium-sparing diuretics.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid foods high in potassium (e.g., bananas, oranges, potatoes, tomatoes, spinach, avocados) and potassium-containing salt substitutes. Do not consume excessive amounts of sodium-rich foods as this solution already contains sodium chloride. Maintain consistent carbohydrate intake if diabetic, as dextrose may affect blood glucose.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride in these concentrations are not teratogenic. There is no evidence of fetal harm from electrolyte and glucose solutions administered IV at recommended doses. Dextrose may cause maternal hyperglycemia if infused rapidly, which can lead to fetal hyperinsulinemia and neonatal hypoglycemia, but this is not a direct teratogenic effect.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, sodium, chloride, and dextrose are normal constituents of breast milk. IV infusion of these electrolytes at typical replacement doses does not result in concentrations significantly exceeding normal milk levels. The M/P ratio is not established; however, no adverse effects on breastfed infants are expected. Use with caution in lactating women, but generally considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Physiological changes in pregnancy (increased plasma volume, enhanced renal clearance, altered glucose metabolism) may require adjustments. Monitor serum potassium and glucose levels frequently; dosing may need to be individualized based on deficits and ongoing losses. No standard dose adjustment is universally recommended; titration guided by lab values and clinical status is essential. Avoid rapid infusion of dextrose to prevent maternal hyperglycemia and fetal hyperinsulinemia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor serum potassium and glucose levels frequently; avoid use in patients with hyperkalemia, severe renal impairment, or uncorrected adrenal insufficiency. Administer via central or peripheral line with large bore to prevent phlebitis. Do not administer simultaneously with blood products. Use with caution in patients with cardiac disease or receiving digitalis due to arrhythmia risk. Inspect for particulate matter; do not use if discolored. Rate of infusion should not exceed 10 m Eq/hour unless in critical care setting with cardiac monitoring.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inform your healthcare provider if you have kidney problems, heart disease, or are on any medications, especially potassium-sparing diuretics or ACE inhibitors.,Report any signs of too much potassium, such as muscle weakness, irregular heartbeat, or tingling in hands/feet.,This medication is given intravenously; tell your nurse if you experience pain, redness, or swelling at the IV site.,Do not consume potassium-rich foods or salt substitutes without consulting your doctor, as this may increase risk of hyperkalemia.,Follow your doctor's instructions for monitoring blood tests, including potassium and glucose levels.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintenance of electrolyte balance; dextrose provides caloric support; sodium chloride provides sodium and chloride ions for fluid and electrolyte replacement.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; adult dose is 1000 m L to 2000 m L per day, providing 20-40 m Eq potassium, 50-100 g dextrose, and 77-154 m Eq sodium, administered at a rate of 125-200 m L/hour based on clinical status and serum potassium.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride in these concentrations are not teratogenic. There is no evidence of fetal harm from electrolyte and glucose solutions administere. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.